GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CytoMed Therapeutics Ltd (NAS:GDTC) » Definitions » Total Current Liabilities

CytoMed Therapeutics (CytoMed Therapeutics) Total Current Liabilities : $0.54 Mil (As of Dec. 2023)


View and export this data going back to 2023. Start your Free Trial

What is CytoMed Therapeutics Total Current Liabilities?

Total current liabilities includes Accounts Payable & Accrued Expense, Short-Term Debt & Capital Lease Obligation, Other Current Liabilities, and Current Deferred Liabilities. CytoMed Therapeutics's total current liabilities for the quarter that ended in Dec. 2023 was $0.54

CytoMed Therapeutics Total Current Liabilities Historical Data

The historical data trend for CytoMed Therapeutics's Total Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CytoMed Therapeutics Total Current Liabilities Chart

CytoMed Therapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Total Current Liabilities
2.05 2.15 3.08 0.54

CytoMed Therapeutics Semi-Annual Data
Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Total Current Liabilities Get a 7-Day Free Trial 2.15 2.22 3.08 0.23 0.54

CytoMed Therapeutics Total Current Liabilities Calculation

Total Current Liabilities is the total amount of liabilities that the company needs to pay over the next 12 months.

CytoMed Therapeutics's Total Current Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=0.392+0.03
+Other Current Liabilities+Current Deferred Liabilities
=0.11+0.006
=0.54

CytoMed Therapeutics's Total Current Liabilities for the quarter that ended in Dec. 2023 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=0.392+0.03
+Other Current Liabilities+Current Deferred Liabilities
=0.11+0.006
=0.54

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The increase of Total Current Liabilities of a company is not necessarily a bad thing. This may conserve the company's cash and contribute positively to cash flow.

Total Current Liabilities is linked to Total Current Assets through the Current Ratio and Working Capital. The Current Ratio is equal to dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations. Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term.

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term

CytoMed Therapeutics Total Current Liabilities Related Terms

Thank you for viewing the detailed overview of CytoMed Therapeutics's Total Current Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

CytoMed Therapeutics (CytoMed Therapeutics) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CytoMed Therapeutics Ltd (NAS:GDTC) » Definitions » Total Current Liabilities
Comparable Companies
OKYO MTNB KA SPRB YS DYAI DTIL COYA AGLE IMUX OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
F98:Germany
Address
1 Commonwealth Lane, No. 08-22 One Commonwealth, Singapore, SGP, 149544
Website
https://w2.cytomed.sg
CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies into creating novel cell-based immunotherapies for the treatment of human cancers. The development of its novel technologies has been inspired by the clinical success of existing CAR-T cells in treating hematological malignancies as well as the current clinical limitations and commercial challenges in extrapolating the CAR-T principle into the treatment of solid tumors. Geographically, the company operates in Singapore and Malaysia which is majority revenue generator.
Executives
Chee Kong Choo director, 10 percent owner COMMONWEALTH LANE 08-22, SINGAPORE U0 149544
Jieming Zeng director, officer: CSO and CMO 1 COMMONWEALTH LANE #08-22, SINGAPORE U0 149544
Shu Wang 10 percent owner 1 COMMONWEALTH LANE #08-22, SINGAPORE U0 149544
Wee Kiat Tan director, officer: Chief Operating Officer 1 COMMONWEALTH LANE #08-22, SINGAPORE U0 149544
Keng Kiat Toh director 1 COMMONWEALTH LANE #08-22, SINGAPORE U0 149544
Glorious Finance Ltd 10 percent owner 18 NAMLY GROVE SOUTH, SINGAPORE U0 267310
Luk Lucas Tien Wee director, officer: Chief Clinical Officer 1 COMMONWEALTH LANE #08-22, SINGAPORE U0 149544
Leong Mark Kei Wei director 1 COMMONWEALTH LANE #08-22, SINGAPORE U0 149544
Chak Hua Yew director 1 COMMONWEALTH LANE #08-22, SINGAPORE U0 149544
Yuin Han Loh director 1 COMMONWEALTH LANE 08-22, SINGAPORE U0 149544